132 related articles for article (PubMed ID: 34030451)
1. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract][Full Text] [Related]
2. Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER.
Endo K; Tanaka H; Matsuo H; Onoda T; Iida A; Ishii T
Anticancer Res; 2024 Jun; 44(6):2653-2660. PubMed ID: 38821611
[TBL] [Abstract][Full Text] [Related]
3. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L
Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102
[TBL] [Abstract][Full Text] [Related]
4. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
5. An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement.
Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].
Cao XN; Li Z; Wang QY
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
[No Abstract] [Full Text] [Related]
7. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature.
Mundada M; Mannan KA; Vasu D; Ahmed F; K S
Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of gastrointestinal SMARCA4-deficient undifferentiated tumors.
Wang J; Elghawy O; Kurpiel B; Kaur V
Clin J Gastroenterol; 2023 Dec; 16(6):807-814. PubMed ID: 37651059
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract][Full Text] [Related]
10. All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
Rekhtman N
Clin Cancer Res; 2024 May; 30(9):1708-1711. PubMed ID: 38416596
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.
Anžič N; Krasniqi F; Eberhardt AL; Tzankov A; Haslbauer JD
Case Rep Oncol; 2021; 14(2):706-715. PubMed ID: 34177520
[TBL] [Abstract][Full Text] [Related]
12. Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations.
Rathbone M; O'Hagan C; Wong H; Khan A; Cook T; Rose S; Heseltine J; Escriu C
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610927
[TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT in a Case of Thoracic SMARCA4-Deficient Undifferentiated Tumor.
Guo J; Liao Z; Chen Q; Dong A; Huang M
Clin Nucl Med; 2023 Dec; 48(12):1111-1113. PubMed ID: 37882056
[TBL] [Abstract][Full Text] [Related]
14. The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation.
Li X; Tian S; Shi H; Ta N; Ni X; Bai C; Zhu Z; Chen Y; Shi D; Huang H; Chen L; Hu Z; Qu L; Fang Y; Bai C
Cancer Gene Ther; 2024 May; 31(5):687-697. PubMed ID: 38347129
[TBL] [Abstract][Full Text] [Related]
15. Identification and Treatment of SMARCA4 Deficient Poorly Differentiated Gastric Carcinoma.
Bhat V; Koneru M; Knapp K; Joneja U; Morrison J; Hong YK
Am Surg; 2023 Nov; 89(11):4987-4989. PubMed ID: 36533880
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.
Wang A; Jin Y; Cao Z; Lu L; Li Z
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38124509
[TBL] [Abstract][Full Text] [Related]
17. PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum: Two case reports.
Shi YN; Zhang XR; Ma WY; Lian J; Liu YF; Li YF; Yang WH
World J Clin Oncol; 2024 Mar; 15(3):456-463. PubMed ID: 38576599
[TBL] [Abstract][Full Text] [Related]
18. Thoracic SMARCA4-Deficient Undifferentiated Tumors With Unusual Presentations: A Case Series.
Helmink AJ; Alshomrani A; Lauer SR; Yuil-Valdes A
Int J Surg Pathol; 2023 Oct; ():10668969231206350. PubMed ID: 37903457
[TBL] [Abstract][Full Text] [Related]
19. Thoracic SMARCA4-deficient undifferentiated tumor with associated granulomatous reaction and response to pembrolizumab.
Marshall M; Khader S; Beasley S; Lajara S
Diagn Cytopathol; 2023 Oct; 51(10):E287-E293. PubMed ID: 37350425
[TBL] [Abstract][Full Text] [Related]
20. Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectives.
Shinno Y; Ohe Y;
Jpn J Clin Oncol; 2024 Mar; 54(3):265-270. PubMed ID: 38117955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
